Top

Published in:

01-01-2016 | Original Article

Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?

Authors: Laura-Maria Krabbe, Aditya Bagrodia, Mary E. Westerman, Bishoy A. Gayed, Ahmed Q. Haddad, Arthur I. Sagalowsky, Shahrokh F. Shariat, Payal Kapur, Yair Lotan, Vitaly Margulis

Published in: World Journal of Urology | Issue 1/2016

Abstract

Purpose

To assess the potential biologic impact of tumor location on oncological outcomes for patients with upper tract urothelial carcinoma (UTUC), we used prospectively collected molecular signatures of high-grade UTUC.

Methods

Immunohistochemical staining for p21, p27, p53, cyclin E, and Ki-67 was prospectively performed on 96 UTUC specimens of patients with non-metastatic high-grade UTUC treated with extirpative surgery. Patients were grouped according to primary tumor location (pelvicalyceal vs. ureteral) where primary tumor was defined as the highest tumor stage and diameter. Primary outcome was assessment of differences in marker expression between groups. Secondary outcome was difference in survival according to marker status.

Results

Pelvicalyceal and ureteral tumors were found in 52.1 and 47.9 %, respectively, and 42.7 % of patients had non-organ-confined disease. Over a median follow-up of 22.0 months, 31.2 and 20.8 % of patients experienced disease recurrence and died of UTUC, respectively. The total number of altered markers stained for was 0–2 in 67.7 and 3–5 in 32.3 % of patients. The number of altered markers and alteration status of markers were not significantly different between patients with primary pelvicalyceal versus ureteral tumors when stratified by tumor stage and nodal status. There were no significant differences in survival outcomes between both groups when stratified by number of altered markers (0–2 and 3–5).

Conclusions

The prospective assessment of selected cell cycle and proliferative markers suggests no molecular difference between UTUC of the pelvicalyceal system and that of the ureter. Our study is limited by its size and definition of location.

Available only for authorised users

Munoz JJ, Ellison LM (2000) Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 164:1523–1525PubMedCrossRef

Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R et al (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184:453–458PubMedCrossRef

Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M et al (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100–114PubMedCrossRef

Favaretto RL, Shariat SF, Savage C, Godoy G, Chade DC, Kaag M et al (2012) Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 109:77–82PubMedPubMedCentralCrossRef

van der Poel HG, Antonini N, van Tinteren H, Horenblas S (2005) Upper urinary tract cancer: location is correlated with prognosis. Eur Urol 48:438–444PubMedCrossRef

Park J, Ha SH, Min GE, Song C, Hong B, Hong JH et al (2009) The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival. J Urol 182:894–899PubMedCrossRef

Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G et al (2009) Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol 182:2177–2181PubMedCrossRef

Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K et al (2010) Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 57:1072–1079PubMedCrossRef

Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M et al (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58:574–580PubMedPubMedCentralCrossRef

10.

Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F et al (2011) Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 60:1258–1265PubMedCrossRef

11.

Milojevic B, Djokic M, Sipetic-Grujicic S, Milenkovic-Petronic D, Vuksanovic A, Bumbasirevic U et al (2012) Upper urinary tract transitional cell carcinoma: location is not correlated with prognosis. BJU Int 109:1037–1042PubMedCrossRef

12.

Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ et al (2012) Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 110:E7–E13PubMedCrossRef

13.

Zhang X, Zhu Z, Zhong S, Xu T, Shen Z (2013) Ureteral tumours showing a worse prognosis than renal pelvis tumours may be attributed to ureteral tumours more likely to have hydronephrosis and less likely to have haematuria. World J Urol 31:155–160PubMedCrossRef

14.

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Ide H et al (2014) Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location. Ann Surg Oncol 21(3):1038–1045PubMedCrossRef

15.

Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y et al (2013) Prospective evaluation of a molecular marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. Eur Urol 64(3):465–471PubMedCrossRef

16.

Krabbe LM, Lotan Y, Bagrodia A, Gayed BA, Darwish OM, Youssef RF et al (2014) Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract: is there evidence for discordant biology? J Urol 191(4):926–931PubMedCrossRef

17.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York

18.

Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M et al (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63(6):1059–1071PubMedCrossRef

19.

Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61:854–855PubMedCrossRef

20.

Krabbe LM, Bagrodia A, Lotan Y, Gayed BA, Darwish OM, Youssef RF et al (2014) Ki-67 is an independent predictor of oncological outcomes in patients with high-grade upper tract urothelial carcinoma: results of a prospective analysis and a review of the literature. J Urol 191(1):28–34PubMedCrossRef

21.

Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ et al (2008) Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112:315–325PubMedCrossRef

Title: Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?
Authors: Laura-Maria Krabbe
Aditya Bagrodia
Mary E. Westerman
Bishoy A. Gayed
Ahmed Q. Haddad
Arthur I. Sagalowsky
Shahrokh F. Shariat
Payal Kapur
Yair Lotan
Vitaly Margulis
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 1/2016
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-015-1584-6

At a glance: The STEP trials

Springer Medicine

Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Open radical cystectomy: still the gold standard for muscle invasive bladder cancer

Evolving concepts in muscle-invasive bladder cancer

Ileal conduit: standard urinary diversion for elderly patients undergoing radical cystectomy

Volumetric measurement of compensatory hypertrophy in the contralateral normal kidney by the tumor growth

Gracilis muscle interposition flap repair of urinary fistulae: pelvic radiation is associated with persistent urinary incontinence and decreased quality of life

Minilaparoscopy in urology: initial results after 32 cases